Tirzepatide: What a Direct Comparison Adds
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Comparing medicines is more informative when they are tested within the same trial. SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity. The 2025 randomized study enrolled 751 participants without type two diabetes and followed treatment for 72 weeks. Participants and researchers knew the assigned medicine. Tirzepatide produced a larger average reduction in body weight and waist circumference under the tested conditions. Gastrointestinal adverse events were common in both groups. This comparison answers a specific weight-management question. It does not identify the best choice for every person or compare every formulation, health outcome, or long-term risk.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Aronne et al. (2025): Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
https://pubmed.ncbi.nlm.nih.gov/40353578/
Primary human randomized phase 3b active-comparator trial

EVIDENCE LIMITATIONS
The study was randomized but open-label.
The tested regimens and population do not cover all indications or individual choices.
Weight loss superiority is not automatic superiority on cardiovascular, functional, or lifelong safety outcomes.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Tirzepatide: What a Direct Comparison Adds